Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized parallel trial of biologicals in rheumatoid arthritis
2012-000139-21Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab, abatacept, rituximab and tocilizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Medical University of Vienna. Primary endpoint: Absolute change in SDAI at 24 weeks. Started Apr 2012; status: completed.
02
Drugs
infliximababataceptrituximabtocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-000139-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000139-21.